Early Access – Where do Payers Stand?

September 12, 2017

This article covers 5 key issues related to payers’ treatment of pricing and reimbursement. Issue 1: It is not rocket science: Less substantiated value propositions for molecules that launch with Phase II data translate into less positive benefit assessments by national agencies. Issue 2: In 2017, payers across the EU and US have shown significant […]